XM does not provide services to residents of the United States of America.
N
N

Novartis

News

Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN

BRIEF-Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN Oct 24 (Reuters) - NOVARTIS AG NOVN.S : RIBOCICLIB (KISQALI®) RECOGNIZED AS CATEGORY 1 PREFERRED BREAST CANCER ADJUVANT TREATMENT BY NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) Source text for Eikon: ID:nGNERj7p9
N

US FDA declines to approve Camurus' rare hormone disorder drug

US FDA declines to approve Camurus' rare hormone disorder drug Oct 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday. WHY IT'S IMPORTANT The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of ev
I
N

Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Oct 18 (Reuters) - Novartis AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI® TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nPn6w07lka Fur
N

Novartis Receives Positive CHMP Opinion For Kisqali

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali Oct 18 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER CHMP RECOMMENDS MARKETING AUTHORIZATION FOR NOVARTIS' KISQALI KISQALI REDUCES RECURRENCE RISK BY 25% IN PHASE III NATALEE
N

S&P 500 ends flat; health insurer declines offset chip gains

LIVE MARKETS-S&P 500 ends flat; health insurer declines offset chip gains Dow ends up ~0.4%, while S&P 500, Nasdaq close roughly flat Utilities lead S&P 500 sector decliners; Energy up most Dollar, crude, gold gain; bitcoin declines U.S. 10-Year Treasury yield jumps to ~4.10% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.